(LXRX) Lexicon Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 724m USD | Total Return: 263.2% in 12m

Drugs, Treatments, Research, Development
Total Rating 40
Safety 30
Buy Signal 0.61
Biotechnology
Industry Rotation: -0.1
Market Cap: 724M
Avg Turnover: 3.36M USD
ATR: 6.18%
Peers RS (IBD): 73.8
Risk 5d forecast
Volatility90.5%
Rel. Tail Risk-16.5%
Reward TTM
Sharpe Ratio1.83
Alpha219.43
Character TTM
Beta1.402
Beta Downside4.872
Drawdowns 3y
Max DD91.83%
CAGR/Max DD-0.11
EPS (Earnings per Share) EPS (Earnings per Share) of LXRX over the last years for every Quarter: "2021-03": -0.15, "2021-06": -0.13, "2021-09": -0.16, "2021-12": -0.17, "2022-03": -0.16, "2022-06": -0.16, "2022-09": -0.13, "2022-12": -0.16, "2023-03": -0.17, "2023-06": -0.22, "2023-09": -0.21, "2023-12": -0.2, "2024-03": -0.2, "2024-06": -0.17, "2024-09": -0.18, "2024-12": -0.09, "2025-03": -0.07, "2025-06": 0.01, "2025-09": -0.04, "2025-12": -0.04,
EPS CAGR: 28.74%
EPS Trend: 66.3%
Last SUE: 0.78
Qual. Beats: 0
Revenue Revenue of LXRX over the last years for every Quarter: 2021-03: 0.027, 2021-06: 0.234, 2021-09: 0.023, 2021-12: 0.014, 2022-03: 0.037, 2022-06: 0.035, 2022-09: 0.039, 2022-12: 0.028, 2023-03: 0.024, 2023-06: 0.317, 2023-09: 0.162, 2023-12: 0.702, 2024-03: 1.13, 2024-06: 1.647, 2024-09: 1.75, 2024-12: 26.554, 2025-03: 1.262, 2025-06: 28.866, 2025-09: 14.182, 2025-12: 5.493,
Rev. CAGR: 279.40%
Rev. Trend: 91.6%
Last SUE: 0.23
Qual. Beats: 0

Warnings

Interest Coverage Ratio -5.2 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: LXRX Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. (LXRX) is a biopharmaceutical company focused on developing and commercializing pharmaceutical products. The biotechnology sector is characterized by high R&D costs and lengthy drug approval processes.

LXRXs primary commercial product is Sotagliflozin, an oral drug for heart failure and type 2 diabetes with chronic kidney disease. The company also has a pipeline of drug candidates, including Sotagliflozin for hypertrophic cardiomyopathy and type 1 diabetes (Phase 3), LX9211 for neuropathic pain (completed Phase 2), and LX9851 for obesity and cardiometabolic disorders. Biopharmaceutical companies often rely on strategic collaborations and licensing agreements to fund development and expand market reach, as exemplified by LXRXs partnerships with Viatris Inc. and Bristol-Myers Squibb Company.

Further research on ValueRay can provide more in-depth analysis of LXRXs financial performance and market position.

Headlines to Watch Out For
  • Sotagliflozin sales drive revenue growth in heart failure market
  • Clinical trial results for LX9211 impact future pipeline value
  • Regulatory approval for new indications expands market opportunity
  • Competition from established cardiovascular treatments limits market share
  • Strategic collaborations provide funding and development expertise
Piotroski VR‑10 (Strict) 0.5
Net Income: -50.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.37 > 0.02 and ΔFCF/TA 23.58 > 1.0
NWC/Revenue: 162.7% < 20% (prev 646.5%; Δ -483.8% < -1%)
CFO/TA -0.37 > 3% & CFO -67.9m > Net Income -50.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.88 > 1.5 & < 3
Outstanding Shares: last quarter (363.4m) vs 12m ago 0.54% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 20.60% > 50% (prev 10.42%; Δ 10.19% > 0%)
Interest Coverage Ratio: -5.19 > 6 (EBITDA TTM -42.7m / Interest Expense TTM 8.34m)
Altman Z'' -15.00
A: 0.44 (Total Current Assets 101.9m - Total Current Liabilities 20.9m) / Total Assets 185.0m
B: -10.91 (Retained Earnings -2.02b / Total Assets 185.0m)
C: -0.18 (EBIT TTM -43.3m / Avg Total Assets 241.7m)
D: -26.05 (Book Value of Equity -2.02b / Total Liabilities 77.4m)
Altman-Z'' Score: -61.23 = D
Beneish M -2.75
DSRI: 0.43 (Receivables 2.38m/3.47m, Revenue 49.8m/31.1m)
GMI: 0.15 (GM 98.86% / 15.24%)
AQI: 2.65 (AQ_t 0.40 / AQ_t-1 0.15)
SGI: 1.60 (Revenue 49.8m / 31.1m)
TATA: 0.09 (NI -50.3m - CFO -67.9m) / TA 185.0m)
Beneish M-Score: -2.75 (Cap -4..+1) = A
What is the price of LXRX shares? As of April 16, 2026, the stock is trading at USD 1.86 with a total of 2,129,577 shares traded.
Over the past week, the price has changed by +11.38%, over one month by +15.53%, over three months by +45.31% and over the past year by +263.21%.
Is LXRX a buy, sell or hold? Lexicon Pharmaceuticals has received a consensus analysts rating of 3.80. Therefor, it is recommend to hold LXRX.
  • StrongBuy: 1
  • Buy: 2
  • Hold: 2
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the LXRX price?
Analysts Target Price 3.4 80.6%
Lexicon Pharmaceuticals (LXRX) - Fundamental Data Overview as of 15 April 2026
P/S = 14.5472
P/B = 6.7568
P/EG = -0.14
Revenue TTM = 49.8m USD
EBIT TTM = -43.3m USD
EBITDA TTM = -42.7m USD
Long Term Debt = 49.4m USD (from longTermDebt, last quarter)
Short Term Debt = 6.24m USD (from shortTermDebt, last quarter)
Debt = 62.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -34.0m USD (recalculated: Debt 62.2m - CCE 96.2m)
Enterprise Value = 690.5m USD (724.5m + Debt 62.2m - CCE 96.2m)
Interest Coverage Ratio = -5.19 (Ebit TTM -43.3m / Interest Expense TTM 8.34m)
EV/FCF = -10.18x (Enterprise Value 690.5m / FCF TTM -67.9m)
FCF Yield = -9.83% (FCF TTM -67.9m / Enterprise Value 690.5m)
 FCF Margin = -136.2% (FCF TTM -67.9m / Revenue TTM 49.8m)
 Net Margin = -101.1% (Net Income TTM -50.3m / Revenue TTM 49.8m)
 Gross Margin = unknown ((Revenue TTM 49.8m - Cost of Revenue TTM 568k) / Revenue TTM)
 Tobins Q-Ratio = 3.73 (Enterprise Value 690.5m / Total Assets 185.0m)
Interest Expense / Debt = 3.26% (Interest Expense 2.03m / Debt 62.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -34.2m (EBIT -43.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.88 (Total Current Assets 101.9m / Total Current Liabilities 20.9m)
Debt / Equity = 0.58 (Debt 62.2m / totalStockholderEquity, last quarter 107.5m)
 Debt / EBITDA = 0.80 (negative EBITDA) (Net Debt -34.0m / EBITDA -42.7m)
 Debt / FCF = 0.50 (negative FCF - burning cash) (Net Debt -34.0m / FCF TTM -67.9m)
 Total Stockholder Equity = 120.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.83% (Net Income -50.3m / Total Assets 185.0m)
RoE = -41.94% (Net Income TTM -50.3m / Total Stockholder Equity 120.0m)
RoCE = -25.54% (EBIT -43.3m / Capital Employed (Equity 120.0m + L.T.Debt 49.4m))
 RoIC = -18.30% (negative operating profit) (NOPAT -34.2m / Invested Capital 186.9m)
 WACC = 10.09% (E(724.5m)/V(786.7m) * Re(10.74%) + D(62.2m)/V(786.7m) * Rd(3.26%) * (1-Tc(0.21)))
Discount Rate = 10.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 21.81%
 [DCF] Fair Price = unknown (Cash Flow -67.9m)
 EPS Correlation: 66.27 | EPS CAGR: 28.74% | SUE: 0.78 | # QB: 0
Revenue Correlation: 91.60 | Revenue CAGR: 279.4% | SUE: 0.23 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.06 | Chg7d=+0.008 | Chg30d=+0.015 | Revisions Net=+0 | Analysts=4
EPS current Year (2026-12-31): EPS=-0.18 | Chg7d=+0.021 | Chg30d=+0.066 | Revisions Net=+3 | Growth EPS=-29.3% | Growth Revenue=-31.9%
EPS next Year (2027-12-31): EPS=-0.21 | Chg7d=+0.005 | Chg30d=+0.020 | Revisions Net=+2 | Growth EPS=-14.9% | Growth Revenue=-42.1%
[Analyst] Revisions Ratio: +0.60 (4 Up / 1 Down within 30d for Current Year)
External Resources
Dataroma Stockcircle